Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?
Open Access
- 28 April 2009
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 100 (9) , 1373-1378
Abstract
Phase-I trials traditionally involve dose-escalation to determine the maximal tolerated dose (MTD). With conventional chemotherapy, efficacy is generally deemed to be dose-dependent, but the same may not be applicable to molecularly targeted agents (MTAs). We analysed consecutive patients included in Phase-I trials at the Royal Marsden Hospital from 5 January 2005 to 6 June 2006. We considered only trials of monotherapy MTAs in which the MTD was defined. Three patient cohorts (A, B, and C) were identified according to the dose received as a percentage of the final trial MTD (0–33%, 34–65%, >66%). Potential efficacy was assessed using the non-progression rate (NPR), that is, complete/partial response or stable disease for at least 3 months by RECIST. A total of 135 patients having progressive disease before enrolment were analysed from 15 eligible trials. Median age was 57 years (20–86); male : female ratio was 1.8 : 1. Cohort A, B, and C included 28 (21%), 22 (16%), and 85 (63%) patients; NPR at 3 and 6 months was 21% and 11% (A), 50% and 27% (B), 31% and 14% (C), respectively, P=0.9. Median duration of non-progression (17 weeks; 95% CI=13–22) was not correlated with the MTD level, P=0.9. Our analysis suggests that the potential for clinical benefit is not confined to patients treated at doses close to the MTD in Phase-I trials of MTAs.Keywords
This publication has 20 references indexed in Scilit:
- Prospective Validation of a Prognostic Score to Improve Patient Selection for Oncology Phase I TrialsJournal of Clinical Oncology, 2009
- Challenges and Pitfalls of Combining Targeted Agents in Phase I StudiesJournal of Clinical Oncology, 2008
- Dose Selection in Phase I Studies: Why We Should Always Go for the Most EffectiveJournal of Clinical Oncology, 2008
- Biomarkers In Early Clinical Trials: the Committed and the SkepticsClinical Cancer Research, 2008
- Dose Selection in Phase I Studies: Why We Should Always Go for the TopJournal of Clinical Oncology, 2008
- Endpoints and other considerations in phase I studies of targeted anticancer therapy: Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT)European Journal of Cancer, 2008
- Biomarkers in Phase I Oncology Trials: Signal, Noise, or Expensive Distraction?Clinical Cancer Research, 2007
- Risks and benefits associated with novel phase 1 oncology trial designsCancer, 2007
- Adaptive dose finding for phase I clinical trials of drugs used for chemotherapy of cancerStatistics in Medicine, 2002
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000